Poolbeg Pharma PLC Immunomodulator I Patent Portfolio Strengthened
20 Setembro 2023 - 3:00AM
RNS Non-Regulatory
TIDMPOLB
Poolbeg Pharma PLC
20 September 2023
Poolbeg Pharma plc
Immunomodulator I Patent Portfolio Strengthened
Notice of allowance for patent grant in Japan
20 September 2023 - Poolbeg Pharma (AIM: POLB, OTCQB: POLBF,
'Poolbeg' or the 'Company'), a clinical-stage biopharmaceutical
company targeting diseases with a high unmet medical need,
announces that it has received a notice of allowance from the
Japanese Patent Office in relation to its Immunomodulator I patent
application.
The claims deemed allowable cover a p38 MAPK (mitogen-activated
protein kinase) inhibitor for use in the treatment of severe
influenza in human patients and strengthens the Company's robust
intellectual property in the territory. Grant of the application as
a patent is expected upon completion of formalities.
Poolbeg has a worldwide licence for POLB 001 for all uses in
humans and is developing a strong IP portfolio with patents in
place, including Immunomodulator I and Immunomodulator II, covering
the use of the class of p38 MAP kinase (mitogen-activated protein
kinase) inhibitors for the treatment of severe influenza and
hypercytokinaemia. The Company has also filed patent applications
to expand its IP around POLB 001 and the use of p38 MAP kinase
inhibitors in new disease areas, such as oncology. This enhances
the value and attractiveness of POLB 001 to potential pharma
partners.
Jeremy Skillington, PhD, Chief Executive Officer of Poolbeg
Pharma, commented: "This milestone is a testament to the uniqueness
of p38 MAPK inhibition as a potential blockbuster treatment for
severe influenza. We are committed to continuing to strengthen the
intellectual property protection of our portfolio of assets into
new jurisdictions to increase their overall value to potential
partners."
Footnote:
Immunomodulator I: Use of p38 MAPK inhibitors for the treatment
of severe influenza
Immunomodulator II: Use of p38 MAPK inhibitors in combination
with antiviral compounds for treatment of severe influenza, and the
use of p38 MAPK inhibitors, alone or in combination with an
antiviral agent, for the treatment of hypercytokinaemia
- Ends -
Enquiries
Poolbeg Pharma Plc
Jeremy Skillington, CEO
Ian O'Connell, CFO +44 (0) 207 183 1499
Cavendish Capital Markets Ltd (Nominated
Adviser & Joint Broker)
Geoff Nash, Charlie Beeson, Nigel
Birks, Harriet Ward (ECM) +44 (0) 207 220 0500
Singer Capital Markets (Joint Broker)
Phil Davies, Sam Butcher +44 (0) 207 496 3000
J&E Davy (Joint Broker)
Anthony Farrell, Niall Gilchrist +353 (0) 1 679 6363
Optimum Strategic Communications +44 (0) 208 078 4357
Nick Bastin, Hana Malik, Vici Rabbetts poolbeg@optimumcomms.com
About Poolbeg Pharma
Poolbeg Pharma specialises in the development of innovative
medicines to address the unmet need in infectious and other
prevalent diseases. Poolbeg Pharma has a disciplined portfolio
approach to mitigate risk, accelerate drug development, and enhance
investor returns. The Company simultaneously advances multiple
programmes in cost-effective clinical trials, rapidly generating
early human safety and efficacy data to enable early partnering /
out-licensing, with the funds generated reinvested in the pipeline.
Poolbeg Pharma also uses AI to interrogate human challenge trial
data sets to quickly identify new targets and drugs, leading to
faster development and greater commercial appeal.
The Company is targeting the growing infectious disease market.
In the wake of the COVID-19 pandemic, infectious disease has become
one of the fastest growing pharma markets and is expected to exceed
$250bn by 2025. Through opportunistic identification of assets
which complement Poolbeg Pharma's existing pipeline, the Company is
progressing programmes in oncology and metabolic syndromes; adding
disease areas with significant addressable markets.
With its initial assets from hVIVO plc , an industry leading
infectious disease and human challenge trials business, Poolbeg
Pharma has access to knowledge, experience, and clinical data from
over 20 years of human challenge trials. The Company is using these
insights to acquire new assets as well as reposition clinical stage
products, reducing spend and risk. Amongst its portfolio of
exciting assets, Poolbeg Pharma has a small molecule
immunomodulator for severe influenza and other acute inflammatory
conditions (POLB 001) which produces a highly significant reduction
in p38 MAP kinase driven cytokines in a clinical setting; a
first-in-class, intranasally administered RNA-based immunotherapy
for respiratory virus infections (POLB 002); and a vaccine
candidate for Melioidosis (POLB 003). The Company is progressing
two A rtificial I ntelligence (AI) P rogrammes to add promising new
assets to its pipeline as well as developing an Oral Vaccine
Programme and an Oral Delivery Programme focussing on metabolic
syndrome related diseases.
For more information, please go to www.poolbegpharma.com or follow us on Twitter and LinkedIn @PoolbegPharma.
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRAVKLFFXKLFBBZ
(END) Dow Jones Newswires
September 20, 2023 02:00 ET (06:00 GMT)
Poolbeg Pharma (LSE:POLB)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Poolbeg Pharma (LSE:POLB)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024